GlassScriptPhysician profile
Elisabeth A Mckeen
NPI 1407852585
$22,299.06
in general payments reported to CMS, 2019-2025
84 companies · $3,468 in 2025
The $3,468 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,570 · 2020: $2,311 · 2021: $2,082 · 2022: $2,809 · 2023: $4,617 · 2024: $4,443 · 2025: $3,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,788 · Long Term Medical Supply Or Device Loan: $2,299 · Education: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,787.50 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $440.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,130.44 | 2019-2025 | Piqray, Kisqali |
| Celgene Corporation | $1,236.92 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $1,236.37 | 2020-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $1,128.29 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Pfizer INC. | $964.43 | 2019-2025 | |
| Seagen INC. | $913.69 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Janssen Biotech, INC. | $903.26 | 2019-2025 | Erleada, Imbruvica, Carvykti |
| Merck Sharp & Dohme LLC | $755.26 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $683.21 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $643.68 | 2019-2024 | Opdivo, Augtyro |
| Abbvie INC. | $561.67 | 2019-2025 | |
| Genentech USA, INC. | $511.42 | 2019-2025 | Itovebi, Phesgo, Polivy |
| Amgen INC. | $509.83 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Astellas Pharma US INC | $498.70 | 2019-2025 | Xtandi, Padcev |
| Eisai INC. | $481.00 | 2019-2025 |
Show all 84 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisabeth Mckeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.